CompletedNCT02821780
CADASIL Disease Discovery
Studying Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Principal Investigator
- Manfred Boehm, M.D.National Heart, Lung, and Blood Institute (NHLBI)
- Enrollment
- 20 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2016 – 2022
Study locations (2)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Nationwide Children s Hospital, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02821780 on ClinicalTrials.govOther trials for Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT05755997CERebrolysin In CADASILEver Neuro Pharma GmbH
- RECRUITINGNCT06148051AusCADASIL: An Australian Cohort of CADASILPerminder Sachdev
- RECRUITINGNCT06938100Genotype, Clinical Features and Imaging of Neuroradiological Abnormalities in CADASILFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNANCT06935578RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNCT05072483Natural History Study of CADASILNational Heart, Lung, and Blood Institute (NHLBI)